Episode Details

Filip Janku, Monte Rosa Therapeutics’ Chief Medical Officer, just cashed in big—selling 41,845 shares for nearly $882K, a record direct sale for him. He first exercised 36K stock options to boost his holdings before hitting the market, a savvy move to convert options into cash while still keeping 66K vested options in play. Despite this major liquidity grab, Janku remains deeply invested in the company’s future. Monte Rosa, a biotech innovator developing oral drugs targeting Myc-driven cancers and autoimmune diseases, has seen its stock soar 400% in a year—despite heavy R&D costs. This sale? Strategic, not panic-driven.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/d71373a9492c3a63